Tennessee is currently home to 1915 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors
NCT05835687
Recruiting
Loc3CAR is a Phase I clinical trial evaluating the use of autologous B7-H3-CAR T cells for participants ≤ 21 years old with primary CNS neoplasms. B7-H3-CAR T cells will be locoregionally administered via a CNS reservoir catheter. Study participants will be divided into two cohorts: cohort A with B7-H3-positive relapsed/refractory non-brainstem primary CNS tumors, and cohort B with diffuse midline gliomas (DMG). Participants will receive four (4) B7-H3-CAR T cell infusions over a 4 week period.... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/11/2024
Locations: St. Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Central Nervous System Neoplasms, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Ependymoma, High Grade Glioma, Glioblastoma, Medulloblastoma
Register for Updates
Study of IDE196 in Patients with Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT03947385
Recruiting
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/11/2024
Locations: The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee
Conditions: Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
Register for Updates
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
NCT02616302
Recruiting
Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth and have a burning feeling in their stomach, chest, or throat, called heartburn. Other symptoms of... Read More
Gender:
ALL
Ages:
Between 2 years and 11 years
Trial Updated:
11/11/2024
Locations: GI for Kids, Knoxville, Tennessee
Conditions: Gastroesophageal Reflux Disease (GERD)
Register for Updates
Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT04903353
Recruiting
This study aims to compare two FDA approved medications (aripiprazole and risperidone) for the treatment of behavioral dysregulation in children with autism spectrum disorders. This trial, done in the context of routine clinical care, will seek to evaluate whether aripiprazole or risperidone is associated with more weight gain in children.
Gender:
ALL
Ages:
17 years and below
Trial Updated:
11/10/2024
Locations: Division of Developmental Medicine, Nashville, Tennessee
Conditions: Weight Gain, Autism Spectrum Disorder, Medication Side Effect
Register for Updates
Neurophysiologic Biomarkers in Rett Syndrome
NCT05932589
Recruiting
The goal of this observational study is to identify candidate biomarkers in individuals with Rett Syndrome (RTT). The main questions it aims to answer are: * Do these biomarkers change during clinical changes in individuals with RTT? * Are biomarkers stable over time in clinically stable individuals? * Do these biomarkers correlate with severity of RTT? Participants will be asked to undergo an electroencephalogram (EEG) with measurements of Evoked Potentials (EP) to measure electrical activity... Read More
Gender:
FEMALE
Ages:
Between 1 year and 18 years
Trial Updated:
11/08/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Rett Syndrome, RTT, Rett Syndrome, Atypical
Register for Updates
Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome
NCT04797780
Recruiting
This study compares the efficacy of Tamibarotene in combination with azacitidine to azacitidine in combination with placebo in participants who are Retinoic Acid Receptor Alpha (RARA) positive, and newly diagnosed with higher-risk myelodysplastic syndrome (HR-MDS), and who have not received treatment for this diagnosis. The primary goal of the study is to compare the complete remission rate between the two treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/08/2024
Locations: TriStar - Sarah Cannon BMT, Nashville, Tennessee
Conditions: Myelodysplastic Syndromes
Register for Updates
Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial
NCT06593106
Recruiting
This clinical trial studies side effects and best treatment time of cryodevitalization in treating patients with early stage (stage I or stage II) lung cancer. Cryodevitalization is a type of cryosurgery that uses a flexible probe (cryoprobe) to kill tumor cells by freezing them. It is delivered at the time of standard diagnostic robotic bronchoscopy. Using cryodevitalization may be safe, tolerable and/or effective in treating patients with early stage lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Stage I Lung Cancer, Stage II Lung Cancer
Register for Updates
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT05693766
Recruiting
This is an open-label, multicenter, two-arm Phase II clinical trial that will evaluate the impact of 2nd line chemotherapy (i.e. capecitabine) on survival in patients with non-Luminal A hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Invasive Mammary Carcinoma, Metastatic Breast Cancer
Register for Updates
A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
NCT05200364
Recruiting
Phase 1 trial to study the safety, pharmacokinetic and Preliminary Efficacy of STRO-002 in combination with Bevacizumab.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Register for Updates
The ACES Study for Aseptic Pleural Effusion
NCT06210685
Recruiting
The study will enroll recurrent aseptic pleural effusion patients who are designated by their physician as needing treatment to control the fluid. Baseline assessment will include a history and physical, chest imaging and quality of life questionnaires. After ACES implantation, patients will remain under hospital care for general observation as per standard-of-care before being discharged home with access to electronic diaries for tracking pain and dyspnea.
Gender:
ALL
Ages:
21 years and above
Trial Updated:
11/05/2024
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Pleural Effusion
Register for Updates
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry
NCT02418442
Recruiting
Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
11/05/2024
Locations: Monroe Carrell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee
Conditions: Rheumatic Joint Disease
Register for Updates
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT05863195
Recruiting
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be removed by surgery (unresectable). HAI uses a catheter to carry a tumor-killing chemotherapy drug called floxuridine directly into the liver. HAI is already approved by the Food and Drug Administration (FDA) for use in metas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2024
Locations: Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee
Conditions: Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Register for Updates